This site is intended only for healthcare professionals residing in Malaysia
Menu
Close
Menu
Close
Piperacillin when used concomitantly with vecuronium has been implicated in the prolongation of the neuromuscular blockade of vecuronium. Due to their similar mechanisms of action, it is expected that the neuromuscular blockade produced by any of the non-depolarising muscle relaxants could be prolonged in the presence of piperacillin.
During simultaneous administration of heparin, oral anticoagulants and other drugs that may affect the blood coagulation system including thrombocyte function, appropriate coagulation tests should be performed more frequently and monitored regularly.
Piperacillin may reduce the excretion of methotrexate; therefore, serum levels of methotrexate should be monitored in patients to avoid substance toxicity.
As with other penicillins, concurrent administration of probenecid and piperacillin/tazobactam produces a longer half-life and lower renal clearance for both piperacillin and tazobactam; however, peak plasma concentrations of either substances are unaffected.
Piperacillin, either alone or with tazobactam, did not significantly alter the pharmacokinetics of tobramycin in subjects with normal renal function and with mild or moderate renal impairment. The pharmacokinetics of piperacillin, tazobactam, and the M1 metabolite were also not significantly altered by tobramycin administration.
No pharmacokinetic interactions have been noted between piperacillin/tazobactam and vancomycin.
Administration of Tazocin may result in a false-positive reaction for glucose in urine using a copper-reduction method. It is thus recommended that glucose tests based on enzymatic glucose oxidase reactions be used.
The direct Coombs test may be positive.
Bio-Rad Laboratories Platelia Aspergillus enzyme immunoassay (EIA) tests may lead to false-positive results for patients receiving Tazocin. Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with Bio‑Rad Laboratories Platelia Aspergillus EIA test have been reported.
Positive test results for the assays listed above in patients receiving Tazocin should be confirmed by other diagnostic methods.
No pharmacokinetic interactions have been noted between piperacillin/tazobactam and vancomycin.
No pharmacokinetic interactions have been noted between piperacillin/tazobactam and vancomycin.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals residing in Malaysia. If you are a member of public wishing to access information on a specific medicine, please consult with your doctor.
This website is brought to you by
Pfizer (Malaysia) Sdn Bhd 197801003134
(40131-T)
Level 10 & 11, Wisma Averis (Tower 2),
Bangsar South, No. 8, Jalan Kerinchi,
59200 Kuala Lumpur, Malaysia.
Tel: 603-2281 6000
Fax: 603-2281 6388
Copyright © 2024 Pfizer Limited. All rights reserved.